Search

Your search keyword '"M. Gattorno"' showing total 55 results

Search Constraints

Start Over You searched for: Author "M. Gattorno" Remove constraint Author: "M. Gattorno" Topic medicine.disease Remove constraint Topic: medicine.disease
55 results on '"M. Gattorno"'

Search Results

1. THU0501 EARLY DIAGNOSIS OF THE AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALPS) IN PATIENTS WITH UNDEFINED AUTOINFLAMMATORY OR AUTOIMMUNE DISORDERS: THE PRACTICAL ROLE OF A FLOW CYTOMETRY PANEL

2. Concurrent Oral 1 - Therapy of rheumatic disease: OP4. Effectiveness of Rituximab in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register (BSRBR)

3. A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra

4. CRYOPYRIN ASSOCIATED PERIODIC SYNDROME

5. Rheumatoid arthritis and other inflammatory joint diseases (human studies) (WS-036)

6. PReS-FINAL-2319: PED-BD cohort 2013: expert consensus classification gives higher sensitivity than the international study group criteria to define Behcet's disease in children

7. PReS-FINAL-2237: The diagnostic challenge of osteolytic bone lesions in autoinflammatory diseases: a case report

8. PReS-FINAL-2333: Long term efficacy of interleukin-1 receptor antagonist (anakinra) in a multicentric cohort of patients affected by idiopathic recurrent pericarditis

9. PReS-FINAL-2324: PAPA syndrome clinical spectrum and IL-1Β release

10. PW03-018 – Efficacy of Anakinra in recurrent pericarditis

11. P03-018 - Diversity in presenting manifestations of AUTOINFL

12. FRI0488 A Phase Iii Pivotal Umbrella Trial of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes (Colchicine Resistant FMF, HIDS/MKD and TRAPS)

13. IL-1 beta receptor antagonist efficacy in the treatment of idiopathic recurrent pericarditis

14. Rapid and sustained effect of anti-TNF treatment in patients with ADA2 deficiency

15. Identification of type I interferonopathies using blood interferon signature: the experience of a pediatric rheumatology center

16. Enlarging the clinical spectrum of SAVI syndrome

17. Recruitment of abundant NK cells to the PFAPA tonsils support the crucial role of innate immunity in pathogenesis of PFAPA syndrome

18. AB0644 B Cell Characterization in ADA2 Deficiency Patients

19. SAT0484 Prevalence of Cecr1 Mutations in Pediatric Patients with Polyarteritis Nodosa, Livedo Reticularis and/or Stroke

20. AB1014 Enlarging the Clinical Spectrum of Sting-Associated Vasculopathy with Onset in Infancy (SAVI)

21. OP0195 Enhanced NLRP3-Dependent Interleukin-1B Secretion Correlates with Disease Activity in Pyogenic Sterile Arthritis Pyoderma Gangrenosum and Severe ACNE (PAPA) Syndrome

22. FRI0526 Long-Term Efficacy of IL-1 Blockers in Papa Patients: Table 1

23. SAT0001 Cryopyrin Associated Periodic Syndromes (CAPS): Investigations on Knock-In Mouse Model to Exploit Novel Approaches for the Modulation of the NLRP3 Inflammasome

24. OP0193 Pyrin and PSTPIP1, Mutated in FMF, PAPA-, and PAMI Syndrome, are Involved in the Hypersecretion of Alarmins MRP8/14

25. THU0528 Severe Erytrodermic Psoriasis and Arthritis as Clinical Presentation of a Card14-Mediated Pustular Psoriasis (CAMPS)

26. Gene expression profiling in understanding the molecular pathogenesis of and response to canakinumab therapy in traps

27. SP0072 Lessons Learned from the Eurofever Project

28. THU0482 Gene Expression Profiling of Whole Blood Samples of TRAPS Patients Shows Insight into the Molecular Pathogenesis of TRAPS and Response to Canakinumab Treatment

29. OP0280 Recurrent Pericarditis in Children and Adolescents: A Large, Multicentric Case-Series and Implications for the Pediatric Rheumatologist

30. Complications of lysinuric protein intolerance must be treated with immunosuppressive drugs

31. PW02-021 - SAA1 is the strongest predictor of AA in TRAPS

32. PW02-009 - PAPA syndrome: results from the Euroefever registry

33. OR10-006 - Canakinumab in patients with TRAPS

34. P03-021 - Characterization of BM-MSC from osteopetrotic mice

35. FRI0026 Evidence for interleukin (IL)-1β pathway activation in monocytes from patients with familial mediterranean fever (fmf) and pyogenic sterile arthritis, pyoderma gangrenosum and acne (papa) syndrome

36. OP0107 Clinical features at presentation in a series of 86 patients with genetically confirmed traps and 33 patients with inflammatory symptoms and the r92q variant from the eurofevers/eurotraps registry

37. AB1191 Within-patient analysis during anakinra and canakinumab treatment in cryopyrin associated periodic syndrome

38. OP0175 The eurofever registry for autoinflammatory disease: Update on enrollment after 2 years

39. SAT0466 PED-BD COHORT 2013: Expert Consensus Classification Gives Higher Sensitivity than the International Study Group Criteria to Define Behcet’s Disease in Children

40. SP0156 What’s new in clinical management of autoinflammatory diseases

41. AB1179 Failure of adalimumab treatment in three patients with papa syndrome

42. THU0396 Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome (TRAPS)

43. FRI0346 PED-BD, cohort study for paediatric behÇet’s disease: Update 2012 reporting 206 patients

44. PW02-008 - TRAPS in the real world: an international registry

45. PW02-010 - The diagnostic challenge of bone lesions in AID

46. PW02-006 - PAPA syndrome clinical spectrum and IL1B release

47. OR5-001 – Characterization of tonsil infiltration in PFAPA

48. OR7-003 – MEFV genotype, IL1B and role of NLRP3 in FMF

49. B cells characterization in ADA2 Deficiency patients

50. PReS-FINAL-2335: Preliminary analysis of 85 patients with mevalonate kinase deficiency from the eurofever registry

Catalog

Books, media, physical & digital resources